IIVS News
IIVS 2023 Impact Report
March 20, 2024I am happy to present to you the Institute for In Vitro Sciences' (IIVS) 2023 annual report, marking my first year serving as President. It has been an honor to lead the IIVS team through a period of growth and transformation, and I am excited to share with you the progress we have made in advancing new approach methodologies in toxicological research. In addition to my appointment, we welcomed ...
IIVS Partners with SkynFuture to Further In Vitro Research Techniques
September 18, 2023IIVS is pleased to announce a partnership with SkynFuture, a cosmetics and skincare brand within the UniAsia cosmetics company. IIVS and SkynFuture will collaborate to develop and optimize human-relevant research and testing methods to assess the safety and efficacy of skincare products, and conduct training and other activities to advance non-animal test methods in China.
IIVS Acquires Licenses to Work with DEA Schedule I Materials
July 29, 2023IIVS is pleased to announce that our lab has acquired the necessary State and Federal licenses required to work with several materials and compounds listed on DEA Schedule 1. These include cannabis and Δ9-THC and related cannabinoids (DEA Drug Codes 7360 & 7370). Our state-of-the art exposure systems include the Vitrocell® VC-1 and Cloud which able to generate smoke and nebulize liquid ...
IIVS and Toxys Enter Into Agreement to Offer ToxTracker® for In Vitro Genetic Toxicity Evaluation
March 9, 2023The Institute for In Vitro Sciences (IIVS) and Toxys have entered into a license agreement that allows IIVS to offer the ToxTracker® assay. ToxTracker is an innovative in vitroassay allowing identification of the genotoxic and potentially carcinogenic properties of novel and existing drugs, (agro)chemicals, cosmetics and other substances without the use of animal testing...
IIVS Toxicologist Presents on Safety Testing in Latin America
September 1, 2022IIVS Toxicologist Dr. Argel Islas-Robles participated last week as speaker on the “In Vitro Science Webinars Series" focusing on the topic of non-Animal Methods for dermal and ocular testing on personal care and cosmetics (presentation in Spanish). This was first in a series of events designed to highlight New Approach Methodologies (NAMs) for human and environmental safety without the use of ...
IIVS Co-Publishes Article on Ocular Animal Model Alternatives
April 20, 2021The human eye may be exposed to chemicals through various situations, such as accidental splashing or exposure to chemical particles, vapours or gases. Workers and consumers are usually advised to immediately wash eyes generously with water following exposure...
IIVS to collaborate with RIFM to develop non-animal technologies for respiratory allergy
March 31, 2021The Institute for In Vitro Sciences (IIVS) and the Research Institute for Fragrance Materials (RIFM) announce a collaboration to develop a non-animal (in vitro) test designed to assess potential respiratory allergens...
Validation of the 3D RSMN Assay
February 10, 2021IIVS is excited to have taken part in the validation of the Reconstructed Skin Micronucleus Assay as a big step towards the establishment of an OECD test guideline. Read the Full Article Here
IIVS e-News – October 2020
September 28, 2020IIVS is pleased to announce that Allison Hilberer will participate in the OECD Test Guidelines Programme Expert Groups (OECD TG EG) for eye and skin irritation, phototoxicity and skin sensitization. Allison is a Toxicologist II and Study Director at IIVS where she oversees the conduct of in vitrostudies in these areas. Allison has also been involved in many validation ...